Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 446, Issue 1, Pages 105-112Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2014.02.043
Keywords
Tigecycline Gastric cancer; Proliferation inhibition; Autophagy
Categories
Funding
- National Basic Research Program of China [2012cb114603]
- National Natural Science Foundation of China [81201551]
- Research Fund for the Doctoral Program of High Education of China [20130182110003]
- Natural Science Foundation of Chongqing [cstc2013jcyjy0007]
- Fundamental Research Funds for the Central Universities [XDJK2013B020, SWU112033]
Ask authors/readers for more resources
Tigecycline acts as a glycylcycline class bacteriostatic agent, and actively resists a series of bacteria, specifically drug fast bacteria. However, accumulating evidence showed that tetracycline and their derivatives such as doxycycline and minocycline have anti-cancer properties, which are out of their broader antimicrobial activity. We found that tigecycline dramatically inhibited gastric cancer cell proliferation and provided an evidence that tigecycline induced autophagy but not apoptosis in human gastric cancer cells. Further experiments demonstrated that AMPK pathway was activated accompanied with the suppression of its downstream targets including mTOR and p70S6K, and ultimately induced cell autophagy and inhibited cell growth. So our data suggested that tigecycline might act as a candidate agent for pre-clinical evaluation in treatment of patients suffering from gastric cancer. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available